Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...

A woman suffering debilitating symptoms is crediting WVU Medicine for giving her her life back after finally receiving a ...

Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...

CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® ...

Shire noted that the study was representative of the full HAE disease spectrum. Overall, 52% of the study’s 125 patients experienced three or more attacks per month at baseline, 65% of patients ...

In a phase 3 trial, the drug significantly reduced investigator-confirmed HAE attacks per month versus ... a measurement of kidney disease progression. It also comes as findings from a ...

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...